Dilip Shanghvi-led Sun Pharma has agreed to acquire US-based drug maker Organon for $11.75 billion in an all-cash deal. Sun will pay $14 per share, a premium of roughly 24% for the NYSE-listed company.
Sun to Soar Globally with Organon
Dilip Shanghvi-led Sun Pharma has agreed to acquire US-based drug maker Organon for $11.75 billion in an all-cash deal. Sun will pay $14 per share, a premium of roughly 24% for the NYSE-listed company.